University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Clin Cancer Res. 2023 Apr 3;29(7):1167-1169. doi: 10.1158/1078-0432.CCR-22-3652.
Myeloid-derived suppressor cells (MDSC) are associated with resistance to anti-PD-1 therapies. All-trans retinoic acid (ATRA) may induce maturation of MDSCs and alter their immunosuppressive effects. Adding ATRA to pembrolizumab may target this resistance mechanism to enhance the overall impact of anti-PD-1-based immunotherapy. See related article by Tobin et al., p. 1209.
髓系来源的抑制细胞（MDSC）与抗 PD-1 治疗的耐药性有关。全反式维甲酸（ATRA）可能诱导 MDSC 的成熟并改变其免疫抑制作用。将 ATRA 添加到 pembrolizumab 中可能靶向这种耐药机制，以增强基于抗 PD-1 的免疫治疗的总体影响。见 Tobin 等人的相关文章，第 1209 页。
